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Purpose or Objective: To evaluate the efficacy and safety of 
stereotactic radiation therapy (SRT) in the treatment of 
patients with recurrent pancreatic adnocarcinoma at the 
stump or abdominal lymph node after surgery. 
 
Material and Methods: Between October 1 2011 and May1 
2015, patients with recurrent pancreatic adnocarcinoma at 
the stump or abdominal lymph nodes after surgery were 
enrolled and treated with SRT at our hospital. The primary 
end-point was overall survival after SRT (OS). Secondary end-
points were: local control rates (LC), time to symptom 
alleviation, and toxicity using the Common Terminology 
Criteria for Adverse Events (CTCAE v4.0). 
 
Results: Twenty-four patients with 24 lesions (17 abdominal 
lymph nodes and 7 stumps) were treated with SRT. Among 
these patients, five patients were presented with abdominal 
lymph node and synchronous metastases in liver and lung. For 
the entire cohort, the median OS from diagnosis and SRT 
were 28.93 months and 12.20 months, respectively. The 6-
month, 12-month, and 24-month actuarial LC rates were 95.2 
%, 83.8% and 62.1% respectively. Symptom alleviation was 
observed in 11 of 14 patients reported symptoms (78.6%) with 
a median of 8 days (range, 1-14 days) after SRT. Nine 
patients (37.5%) experienced CTCAE v4.0 Grade 1 to 2 acute 
toxicities; one patient experienced grade 3 acute toxicity due 
to thrombocytopenia. 
 
Conclusion: SRT is a safe and efficacious treatment modality 
for patients with recurrent pancreatic adnocarcinoma at the 
stump or abdominal lymph nodes after surgery. Further 
studies are needed before SRT can be recommended 
routinely. 
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Purpose or Objective: Based on the results of the 
intergroup-0123/RTOG 94-05 trial that demonstrated no 
benefit of dose escalation over 50.4 Gy in definitive 
chemoradiotherapy (CRT) for esophageal carcinoma, 50.4 Gy 
appears to be accepted as a standard dose. Radiobiologically, 
however, higher radiation doses, if safely delivered, could 
lead to better local control. We have used combination of 
standard FP (5-fluorouracil [5-FU] and cisplatin) 
chemotherapy and radiation with doses ≥60 Gy in the 
treatment of non-metastatic esophageal cancer. We report 
clinical outcome of the treatment protocol. 
 
Material and Methods: Between 2002 and 2014, 86 patients 
with stage I-III or IV (M1 LYM) esophageal cancer were 
treated with CRT. Median age of the patients was 68 years 
(range: 46 to 84); 76 were men and 10 were women. 
Histology was squamous cell carcinoma in 98%. Patients were 
divided into 4 groups according to the stage and operability; 
Group 1: stage I patients (n = 10); Group 2: stage II-III 
operable patients (n = 20); Group 3: stage II-III (non-T4) 
inoperable patients (n = 21); and Group 4: stage III-IV (T4/M1 
LYM) patients (n = 35). Chemotherapy protocols were either 
cisplatin (70 mg/m2) plus 5-FU (700 mg/m2 x 4 days) 
administered every 4 weeks or low-dose daily cisplatin (4 
mg/m2) and 5-FU (200 mg/m2). Radiation was given by 10-
MV X rays with a daily fraction of 1.8-2 Gy. Treatment 
volume included primary tumor plus regional lymph nodes. A 
total dose between 60 and 70 Gy was chosen depending on 
the treatment volume. Median radiation dose was 64 Gy 
(range: 50-70 Gy; 5 patients could not complete planned 
treatment). Failure was confirmed by pathology or findings of 
progressive disease on serial endoscopy and/or imaging 
studies. Overall survival (OS) and locoregional control (LC) 
rates were calculated by the Kaplan-Meier method. Toxicities 
were evaluated by the Common Terminology Criteria for 
Adverse Events version 4.0. 
 
Results: For all 86 patients, the 3-year LC and OS rates were 
65% and 29%, respectively; they were 100% and 100%, 
respectively, in Group 1, and 72% and 42%, respectively, in 
Group 2. The 2-year LC and OS were 53% and 14%, 
respectively, in Group 3, and 69% and 25%, respectively, in 
Group 4. Overall response rate was 78% (complete response 
in 31 and partial response in 36). Grade 3 or higher acute 
toxicities, mainly hematological, were observed in 37% of the 
patients and 10% experienced grade 3 or higher late 
toxicities. 
 
Conclusion: CRT with FP and 60-70 Gy of radiation appears to 
be tolerable for patients with esophageal cancer. Although 
outcome of this treatment in inoperable patients is not 
satisfactory, the 3-year LC of 100% for stage I patients and 
76% for stage II-III operable patients appear promising. 
Further investigation is warranted to clarify the optimal 
radiation dose in CRT for esophageal cancer. 
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Purpose or Objective: The objective of this study was to 
investigate the prognostic value of circulating lymphocyte 
level at the beginning of postoperative chemoradiotherapy 
(CRT) in pancreatic adenocarcinoma. 
 
Material and Methods: From 2007 to 2014, 41 patients 
treated with postoperative CRT were analyzed. The median 
dose of radiotherapy was 50.4 Gy (range, 45 – 59.4) and 
chemotherapy was administered after surgery. Absolute 
lymphocyte counts (ALC) was obtained from complete blood 
count tests performed prior to CRT. We analyzed blood 
lymphocyte count as well as clinical parameters to identify 
prognostic factor 
 
Results: With a median follow-up of 16.9 months, 32 patients 
had cancer recurrence and 28 died from the disease. The 
median overall survival (OS) and disease free survival (DFS) 
were 19.7 months and 9.8 months. The median OS of high 
postoperative ALC (>2.074 ×10³/ μL) group was significantly 
longer than that of the lower ALC group (32.0 months versus 
17.0 months, p = 0.007). In multivariate analysis, high 
postoperative ALC was a good prognostic factor for OS. 
(Hazard Ratio = 0.341, CI, 0.149 – 0.778, p = 0.011). High ALC 
at the beginning of postoperative CRT was also a prognostic 
factor for DFS in multivariate analysis (Hazard Ratio = 0.452, 
CI, 0.215 – 0.946, p = 0.035). 
 
 
 
